对在耐氟喹诺酮类药物的结核分枝杆菌临床菌株中发现的A亚基第88位携带突变的DNA促旋酶突变酶进行功能分析。
Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
作者信息
Matrat Stéphanie, Veziris Nicolas, Mayer Claudine, Jarlier Vincent, Truffot-Pernot Chantal, Camuset Juliette, Bouvet Elisabeth, Cambau Emmanuelle, Aubry Alexandra
机构信息
Laboratoire de Bactériologie, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, site Pitié-Salpêtrière, Université Paris 6, Assistance Publique-Hôpitaux de Paris, Paris, France.
出版信息
Antimicrob Agents Chemother. 2006 Dec;50(12):4170-3. doi: 10.1128/AAC.00944-06. Epub 2006 Oct 2.
Abstract
We investigated the enzymatic efficiency and inhibition by quinolones of Mycobacterium tuberculosis DNA gyrases carrying the previously described GyrA G88C mutation and the novel GyrA G88A mutation harbored by two multidrug-resistant clinical strains and reproduced by site-directed mutagenesis. Fluoroquinolone MICs and 50% inhibitory concentrations for both mutants were 2- to 43-fold higher than for the wild type, demonstrating that these mutations confer fluoroquinolone resistance in M. tuberculosis.
摘要
我们研究了携带先前描述的GyrA G88C突变以及两种耐多药临床菌株所具有并通过定点诱变重现的新型GyrA G88A突变的结核分枝杆菌DNA促旋酶的酶促效率及喹诺酮类药物对其的抑制作用。两种突变体的氟喹诺酮最低抑菌浓度（MIC）和50%抑制浓度比野生型高2至43倍，表明这些突变赋予结核分枝杆菌对氟喹诺酮类药物的耐药性。
相似文献
1
Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones.
Antimicrob Agents Chemother. 2006 Dec;50(12):4170-3. doi: 10.1128/AAC.00944-06. Epub 2006 Oct 2.
2
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
Antimicrob Agents Chemother. 2006 Jan;50(1):104-12. doi: 10.1128/AAC.50.1.104-112.2006.
3
Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
Diagn Microbiol Infect Dis. 2012 Jul;73(3):260-3. doi: 10.1016/j.diagmicrobio.2012.03.025. Epub 2012 May 4.
4
Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
Int J Antimicrob Agents. 2012 May;39(5):435-9. doi: 10.1016/j.ijantimicag.2012.01.007. Epub 2012 Mar 13.
5
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5189-97. doi: 10.1128/AAC.00539-16. Print 2016 Sep.
6
gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China.
Int J Antimicrob Agents. 2012 Jun;39(6):486-9. doi: 10.1016/j.ijantimicag.2012.02.015. Epub 2012 Apr 21.
7
DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2011 Oct;55(10):4524-9. doi: 10.1128/AAC.00707-11. Epub 2011 Jul 18.
8
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Antimicrob Agents Chemother. 1996 Aug;40(8):1768-74. doi: 10.1128/AAC.40.8.1768.
9
Multiplex allele-specific PCR combined with PCR-RFLP analysis for rapid detection of gyrA gene fluoroquinolone resistance mutations in Mycobacterium tuberculosis.
J Microbiol Methods. 2012 Jan;88(1):175-8. doi: 10.1016/j.mimet.2011.10.015. Epub 2011 Nov 13.
10
Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone.
Antimicrob Agents Chemother. 2011 Aug;55(8):3958-60. doi: 10.1128/AAC.00417-10. Epub 2011 May 9.
引用本文的文献
1
Structural insight in understanding the impact of mutation at position 88 and 94 of DNA gyrase A of Mycobacterium tuberculosis in developing resistance against delafloxacin.
J Biol Phys. 2025 Jun 10;51(1):21. doi: 10.1007/s10867-025-09686-6.
2
How do Mutations of Mycobacterium Genes Cause Drug Resistance in Tuberculosis?
Curr Pharm Biotechnol. 2024;25(6):724-736. doi: 10.2174/0113892010257816230920053547.
3
Evybactin is a DNA gyrase inhibitor that selectively kills Mycobacterium tuberculosis.
Nat Chem Biol. 2022 Nov;18(11):1236-1244. doi: 10.1038/s41589-022-01102-7. Epub 2022 Aug 22.
4
Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis.
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01663-20.
5
Genomic Analysis of Mycobacterium tuberculosis Isolates and Construction of a Beijing Lineage Reference Genome.
Genome Biol Evol. 2020 Feb 1;12(2):3890-3905. doi: 10.1093/gbe/evaa009.
6
A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.
J Antimicrob Chemother. 2016 Sep;71(9):2419-27. doi: 10.1093/jac/dkw168. Epub 2016 Jun 3.
7
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2090-6. doi: 10.1128/AAC.01049-15. Print 2016 Apr.
8
Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases.
J Clin Microbiol. 2015 May;53(5):1473-83. doi: 10.1128/JCM.02993-14. Epub 2015 Feb 11.
9
Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2015 Mar;59(3):1519-24. doi: 10.1128/AAC.04058-14. Epub 2014 Dec 22.
10
Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
J Antibiot (Tokyo). 2015 Jan;68(1):63-6. doi: 10.1038/ja.2014.95. Epub 2014 Jul 23.
本文引用的文献
1
Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand.
Southeast Asian J Trop Med Public Health. 2005;36 Suppl 4:228-37.
2
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.
Antimicrob Agents Chemother. 2006 Jan;50(1):104-12. doi: 10.1128/AAC.50.1.104-112.2006.
3
Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
Antimicrob Agents Chemother. 2005 Feb;49(2):488-92. doi: 10.1128/AAC.49.2.488-492.2005.
4
Geographically dependent distribution of gyrA gene mutations at codons 83 and 87 in Salmonella Hadar, and a novel codon 81 Gly to His mutation in Salmonella Enteritidis.
APMIS. 2004 Mar;112(3):165-71. doi: 10.1111/j.1600-0463.2004.apm1120302.x.
5
Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases.
Annu Rev Biophys Biomol Struct. 2004;33:95-118. doi: 10.1146/annurev.biophys.33.110502.140357.
6
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.
Antimicrob Agents Chemother. 2004 Apr;48(4):1281-8. doi: 10.1128/AAC.48.4.1281-1288.2004.
7
Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis.
Am J Respir Crit Care Med. 2004 May 15;169(10):1103-9. doi: 10.1164/rccm.200308-1159OC. Epub 2004 Jan 23.
8
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
Antimicrob Agents Chemother. 2004 Feb;48(2):596-601. doi: 10.1128/AAC.48.2.596-601.2004.
9
Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
J Antimicrob Chemother. 2003 May;51(5):1109-17. doi: 10.1093/jac/dkg222. Epub 2003 Apr 14.
10
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.
Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. doi: 10.1164/rccm.167.4.603.
Zotero 插件